Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Hospital Universitario de San Vicente Fundación, Medellín, Colombia.
Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú.
Lupus. 2021 Feb;30(2):181-203. doi: 10.1177/0961203320979051. Epub 2020 Dec 13.
During the last decades, there has been an increased interest in the discovery and validation of biomarkers that reliably reflect specific aspects of lupus. Although many biomarkers have been developed, few of them have been validated and used in clinical practice, but with unsatisfactory performances. Thus, there is still a need to rigorously validate many of these novel promising biomarkers in large-scale longitudinal studies and also identify better biomarkers not only for lupus diagnosis but also for monitoring and predicting upcoming flares and response to treatment. Besides serological biomarkers, urinary and cerebrospinal fluid biomarkers have emerged for assessing both renal and central nervous system involvement in systemic lupus erythematosus, respectively. Also, novel omics techniques help us to understand the molecular basis of the disease and also allow the identification of novel biomarkers which may be potentially useful for guiding new therapeutic targets.
在过去的几十年中，人们对发现和验证能够可靠反映狼疮特定方面的生物标志物产生了浓厚的兴趣。尽管已经开发出许多生物标志物，但其中很少有经过验证并在临床实践中使用，而且效果并不理想。因此，仍然需要在大规模的纵向研究中严格验证其中许多有前途的新型生物标志物，并确定不仅用于狼疮诊断而且用于监测和预测即将发生的发作以及对治疗反应的更好的生物标志物。除了血清学生物标志物外，尿液和脑脊液生物标志物也分别用于评估系统性红斑狼疮的肾脏和中枢神经系统受累。此外，新型组学技术有助于我们了解疾病的分子基础，还可以识别出可能对指导新的治疗靶点有用的新型生物标志物。
